Difference between revisions of "Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
Line 8: | Line 8: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Vismodegib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Vismodegib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
− | + | ||
− | |||
− | |||
− | |||
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" |
Revision as of 00:26, 27 July 2022
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
Regimen
Study | Evidence |
---|---|
Hainsworth et al. 2018 (MyPathway) | Phase 2a |
Eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
Targeted therapy
- Vismodegib (Erivedge) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed